• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


Prices delayed by at least 15 minutes | Print

Exelixis (EXEL)

Common Shares
Sell: $21.23|Buy: $22.5|Change: 0.22 (-0.99%)

This share can be held in a Dealing accountISALifetime ISAJISASIPP

Company profile

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Address

1851 Harbor Bay Parkway
Alameda
CA
USA
94502

Telephone

+1 650 8378194

Website

https://www.exelixis.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Exelixis Inc Annual General Meeting for 20252025-05-30T09:00:00
Exelixis Inc First Quarter Earnings Conference Call for 20252025-04-30T17:00:00
Exelixis Inc First Quarter Earnings Results for 20252025-04-30T00:00:00
Exelixis Inc Fourth Quarter Earnings Conference Call for 20242025-02-06T17:00:00
Exelixis Inc Fourth Quarter Earnings Results for 20242025-02-06T00:00:00
Exelixis Inc Annual Report for 20242025-02-06T00:00:00
Exelixis Inc Third Quarter Earnings Conference Call for 20242024-11-01T17:00:00
Exelixis Inc Third Quarter Earnings Results for 20242024-11-01T00:00:00
Exelixis Inc Second Quarter Earnings Conference Call for 20242024-08-01T17:00:00
Exelixis Inc Second Quarter Earnings Results for 20242024-08-01T00:00:00
Exelixis Inc Annual General Meeting for 20242024-05-30T09:00:00

Previous key dates

NameKey Date
Exelixis Inc Annual General Meeting for 20242024-05-30T09:00:00
Exelixis Inc First Quarter Earnings Conference Call for 20242024-04-30T17:00:00
Exelixis Inc First Quarter Earnings Result for 20242024-04-30T00:00:00
Exelixis Barclays 26th Annual Global Healthcare Conference2024-03-13T00:00:00
Exelixis Leerink Partners Global Biopharma Conference 20242024-03-12T09:20:00
Exelixis TD Cowen 44th Annual Health Care Conference2024-03-05T10:30:00
Oppenheimer 34th Annual Healthcare Life Sciences Conference2024-02-13T12:40:00
6th Annual Biotechnology Conference2024-02-08T09:00:00
Exelixis Inc Fourth Quarter Earnings Conference Call for 20232024-02-06T17:00:00
Exelixis Inc Fourth Quarter Earnings Result for 20232024-02-06T00:00:00
Exelixis Inc Annual Report for 20232024-02-06T00:00:00
Exelixis Inc Third Quarter Earnings Conference Call for 20232023-11-01T17:00:00
Exelixis Inc Third Quarter Earnings Result for 20232023-11-01T00:00:00
Exelixis Inc Second Quarter Earnings Conference Call for 20232023-08-01T17:00:00
Exelixis Inc Second Quarter Earnings Result for 20232023-08-01T00:00:00
Exelixis Inc Annual General Meeting for 20232023-05-31T00:00:00
Exelixis Inc First Quarter Earnings Conference Call for 20232023-05-09T17:00:00
Exelixis Inc First Quarter Earnings Result for 20232023-05-09T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.